Galectin Therapeutics INC 8-K Filing

FAQ

Key Financial Figures

• $0.001 — hange on which registered Common Stock $0.001 par value per share GALT The Nasdaq
• $10.00 million — e the Company a line of credit of up to $10.00 million (the "Line of Credit") to finance the C
• $10.00 — ng such draw, but in no event more than $10.00 per share nor less than the closing pri

Filing Documents

• ef20061484_8k.htm (8-K) — 35KB
• ef20061484_ex4-1.htm (EX-4.1) — 49KB
• ef20061484_ex10-1.htm (EX-10.1) — 106KB
• ef20061484_ex10-2.htm (EX-10.2) — 10KB
• ef20061484_ex99-1.htm (EX-99.1) — 15KB
• image00005.jpg (GRAPHIC) — 5KB
• 0001140361-25-046115.txt ( ) — 393KB
• galt-20251219.xsd (EX-101.SCH) — 4KB
• galt-20251219_lab.xml (EX-101.LAB) — 21KB
• galt-20251219_pre.xml (EX-101.PRE) — 16KB
• ef20061484_8k_htm.xml (XML) — 4KB

01

Item 1.01. Entry into a Material Definitive Agreement. On December 19, 2025, Galectin Therapeutics Inc. (the "Company") and Richard E. Uihlein (the "Lender") entered into a Line of Credit Letter Agreement (the "December 2025 Supplemental Line of Credit Agreement"), pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million (the "Line of Credit") to finance the Company's working capital needs. The Company may draw upon the Line of Credit through January 31, 2027. Each advance made pursuant to the December 2025 Supplemental Line of Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a "Promissory Note," and collectively, the "Promissory Notes"), and bear interest at the Applicable Federal Rate for short term loans (currently 3.60%), plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before June 30, 2027. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid. At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company's common stock (the " Common Stock ") equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than the closing price per share on December 19, 2025. In connection with the December 2025 Supplemental Line of Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 200,000 shares of the Company's common stock, par value $0.001 per share (collectively, the "Warrants"). The Company shall issue to the Lender Warrants to purchase up to the remaining 200,000 shares of the Company's common stock, ratably, upon borrowings under the December 2025 Sup

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 4. 1 Form of Warrant. 10. 1 December 2025 Supplemental Line of Credit Letter Agreement, dated as of December 19, 2025, by and between Richard E. Uihlein and the Company. 10. 2 Form of Convertible Promissory Note. 99. 1 Press Release dated December 19, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALECTIN THERAPEUTICS INC. Date: December 19, 2025 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR